NCT06574763View on ClinicalTrials.gov

Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2026

Conditions
Ovarian Cancer
Interventions
DRUG

RC48/Carboplatin

RC48, 2.5mg/kg, iv, Q3W Carboplatin, AUC 5, iv, D1, Q3W

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT06574763 - Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer | Biotech Hunter | Biotech Hunter